Navigation Links
Drug Effective Against Heart-Lung Disorder
Date:6/19/2008

Bosentan slowed decline linked to pulmonary arterial hypertension, study found

THURSDAY, June 19 (HealthDay News) -- The drug bosentan reduced clinical decline in patients with early-stage pulmonary arterial hypertension (PAH), Italian researchers report.

PAH is a progressive disease in which increased pulmonary resistance in the lungs causes structural damage to the heart, eventually leading to heart failure and death.

Previous studies have shown that bosentan improves exercise capacity and pulmonary vascular resistance (PVR) and slows clinical decline in patients with later stages of PAH.

This new study included 185 people, ages 12 and over, with early-stage PAH who were divided into two groups. One group received bosentan, and the other group received a placebo. The patients' PVR and distance they could walk in six minutes were measured at the start of the study and again six months later.

After six months, the mean PVR improved at a significant rate for those on bosentan versus those on placebo, wrote Professor Nazzareno Galie, of the Institute of Cardiology at the University of Bologna, and colleagues.

The mean six-minute walk distance also increased 11.2 meters in the bosentan group from 438 meters at baseline, compared to a decrease from 431 meters to 423 meters in the placebo group. However, these changes in distance weren't clinically significant.

Three percent of patients in the bosentan group and 14 percent of those in the placebo group experienced clinical worsening events, such as symptomatic progression of PAH, hospitalization and death. This difference was statistically significant.

Thirteen percent of patients in the bosentan group and 9 percent of those in the placebo group reported serious adverse events. Fainting was the most common adverse event in the bosentan group, and right ventricular failure was the most common in the placebo group.

The findings are in the June 21 issue of The Lancet.

"This study broadens the potential for bosentan as a treatment in pulmonary arterial hypertension, and the evidence presented by (the researchers) should soon be translated into clinical practice," Dr. Neeraj Dhaun and Professor David Webb, Queen's Medical Research Institute, University of Edinburgh, U.K., wrote in an accompanying comment.

More information

The U.S. National Heart, Lung, and Blood Institute has more about PAH.



-- Robert Preidt



SOURCE: The Lancet, news release, June 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Build and Maintain an Effective Competitive Intelligence Group
2. Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey
3. HIV Tests Cost-Effective for Some Seniors
4. Effective health messages may yield vaccine compliance among ER workers
5. Effective treatment for sickle cell underused by doctors
6. Effective Communication of Clinical Studies for Maximum Impact
7. Winning Method - Effective Identification and Development of Clinical Investigators
8. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
9. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
10. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
11. Tracking Cancer Drugs Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Effective Against Heart-Lung Disorder
(Date:2/13/2016)... ... February 13, 2016 , ... ... Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... learn how to start an IV and draw blood, combining technology with traditional ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House ... Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. , ... the love of a Buddhist teacher for teaching and helping others. Valentine’s Day ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 ... ... Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... issue in the life cycle of pharmaceutical products, garnering increased attention from all ...
(Date:2/12/2016)... Wis. (PRWEB) , ... February 12, 2016 , ... ... second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. ... practice new behaviors and create new habits. The workshops cover a broad range ...
(Date:2/12/2016)... ... 2016 , ... The Jones Agency, a family owned insurance company with offices ... cooperative charity drive with the Tarrant Area Food Bank in the hopes of alleviating ... in need, the Tarrant County Food Bank offers hope and security to the one ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
(Date:2/11/2016)... 2016  Governor Andrew M. Cuomo today announced a ... throughout Western New York . This ... Polytechnic Institute, includes a major expansion of Athenex,s North ... Buffalo , as well as the creation of ... Dunkirk . The combined projects are expected ...
Breaking Medicine Technology: